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ABSTRACT
Introduction The burden of atrial fibrillation (AF) in 
Thailand is high and associated with increased morbidity, 
mortality and healthcare costs. Vitamin K antagonists 
(eg, warfarin), commonly used for stroke prevention in 
patients with AF in Thailand, are effective but are often 
suboptimally controlled. We aim to evaluate the impact 
of an SAMe- TT2R2 score- guided strategy and educational 
intervention compared to usual care on anticoagulation 
control expressed by the time in therapeutic range (TTR) at 
12 months, in anticoagulant- naïve Thai patients with AF.
Methods and analysis Multicentre, open- label, parallel- 
group, randomised controlled trial conducted in Thailand 
among adult patients (age: 18 years) with AF who are 
anticoagulant naïve. Patients will be randomised to one 
of two groups; an SAMe- TT2R2 score- guided strategy 
with educational intervention and usual care versus 
usual care alone. The planned follow- up period is 12 
months. The primary outcome is TTR at 12 months. 
Secondary outcomes include: (1) TTR at 6 months; (2) 
thromboembolic and bleeding events at 12 months; 
(3) composite major adverse cardiovascular events at 
12 months; (4) change in patients’ knowledge of AF 
between baseline and 6 months and 12 months; (5) cost 
effectiveness; (6) quality of life at baseline, 6 months and 
12 months using EQ- 5D- 5L (Thai version) and (7) patient 
satisfaction/perceptions of the TREAT intervention. An 
embedded qualitative study will assess patient perceptions 
of the TREAT intervention.
Ethics and dissemination The study has been approved 
by the Ethical Review Committee, Ministry of Public Health 
of Thailand, and registered in the Thai Clinical Trials 
Registry. The results of this trial will be submitted for 
publication in a peer- reviewed journal. Participants will be 
informed via a link to a preview of the publication. A lay 
summary will also be provided to all participants prior to 
publication.
Trial registration number TCTR20180711003.
INTRODUCTION
Atrial fibrillation (AF) is associated with 
decreased quality of life, and increased 
mortality and morbidity from stroke/throm-
boembolism.1 2 Incidence of AF has been 
Strengths and limitations of this study
 ► Warfarin remains the default therapy for stroke pre-
vention in atrial fibrillation (AF) in many countries, 
but is often suboptimally managed.
 ► A one- time structured educational- behavioural in-
tervention (TREAT intervention) among those pre-
dicted to be less likely to achieve optimal control 
may be a simple and cost- effective adjunct man-
agement strategy, which could help improve time in 
therapeutic range.
 ► This prospective individually randomised controlled 
trial in anticoagulant- naïve patients with AF aims to 
assess whether the application of an SAMe- TT2R2 
score- guided strategy and TREAT intervention plus 
usual care could improve anticoagulation control 
with warfarin.
 ► The study design has a multidisciplinary team ap-
proach, and the efficacy, safety, patients’ satisfac-
tion as well as cost effectiveness will be assessed.
 ► One challenge of the study, if implemented, is to 
standardise the quality of usual care and TREAT in-
tervention among centres.
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increasing in developing countries, including Thailand, 
partly due to the rapid change of population dynamics 
towards an ageing society.3 4 The hospitalisation rate for 
Thai patients with AF was high (15.5 per 100 000 person- 
years), with a high mortality (44.0% after 72- month 
follow- up (average 46 months)).5 The high burden of AF 
in Thailand is also associated with similarly high health-
care costs.6
Appropriate oral anticoagulation, either with a vitamin 
K antagonist (VKA, eg, warfarin) or with a non- VKA oral 
anticoagulants (NOAC), is essential for effective stroke 
prevention in patients with AF with one or more stroke 
risk factors.7 Despite the advantages of NOAC over VKA, 
the access of NOAC are generally limited due to cost. 
Hence, VKAs are widely used globally.8 9 In Thailand, 
warfarin is the default therapy for stroke prevention in 
AF but is often suboptimally managed due to the many 
inherent limitations associated with this drug, including 
diet, drug and alcohol interactions and difficulties with 
anticoagulation monitoring. Recent data from retro-
spective cohort studies, along with a nationwide registry, 
suggested that the average time in therapeutic range 
(TTR) among patients with AF in Thailand ranged from 
50% to 55%.10–13 Those with suboptimal anticoagulation 
control, TTR <65%, had a twofold–threefold increased 
risk of stroke, major bleeding and death compared with 
those with TTR ≥65%.12 As a result, strategies to improve 
TTR control are clearly needed and would likely have a 
major impact on preventing these adverse events.
TTR is influenced by numerous modifiable and non- 
modifiable factors, but the more common clinical factors 
have been used to formulate the SAMe- TT2R2 score 
(table 1).14
Several observational studies including those conducted 
in Asian populations, have demonstrated that an SAMe- 
TT2R2 value of >2 is predictive of poor TTR, all- cause 
mortality and the composite endpoint of thromboembolic 
events, major bleeding and mortality.13 15–17 By identifying 
those who are at risk of poor TTR, targeted efforts to 
improve TTR can be effectively provided to the vulner-
able group. If TTR can be improved to >65%, VKAs can 
provide comparable efficacy and safety to that seen with 
NOACs.18 19 Previo studies have demonstrated that many 
patients with AF possess little knowledge about AF and do 
not understand the risks/benefits of OAC,20–25 and this 
may contribute to poor international normalised ratio 
(INR) control.
We have previously shown that an educational- 
behavioural intervention (TREAT, ISRCTN93952605) 
significantly improved TTR 6 months after warfarin initi-
ation compared with usual care alone (78.5% vs 66.7%, 
respectively; p=0.01).26–28 Thus, a one- time structured 
educational- behavioural intervention among those 
predicted to be less likely to achieve good INR control 
may be a simple and cost- effective adjunct management 
strategy, which could help improve individual TTR. 
Increased patient understanding of disease and treat-
ment, and a reduction of adverse events, may improve 
quality of life.
We, therefore, conducted a prospective individually 
randomised controlled trial (RCT) in anticoagulant- 
naïve Thai patients with AF to assess whether the applica-
tion of an SAMe- TT2R2 score- guided strategy and TREAT 
intervention26–28 plus usual care could improve anticoag-
ulation control with warfarin (measured by percentage 
TTR) at 12 months (primary outcome) compared with 
usual care alone.
Objectives
The primary objective of this study is to evaluate the impact 
of an SAMe- TT2R2 score- guided strategy and educational 
intervention (plus usual care) compared with usual care 
alone, on patient’s anticoagulation control with warfarin, 
as measured by the TTR at 12 months, in anticoagulant- 
naïve Thai patients with AF. As secondary objectives, 
we aim to evaluate the impact of this intervention on 
patient knowledge, TTR at 6 months, thromboembolic 
and bleeding events and the composite major adverse 
cardiovascular events (MACE). We will also perform anal-
ysis to evaluate the cost effectiveness of the intervention 
and investigate patients’ satisfaction and acceptance of 
the TREAT intervention using a brief questionnaire and 
further in a qualitative sub- study.
METHODS
Study design and setting
This is a multicentre, open- label, paralleled- group, RCT 
conducted among adult Thai patients (age: ≥18 years) 
with AF who are anticoagulant naïve. Patients who are 
eligible for stroke prevention according to the ESC 
Guidelines for the diagnosis and management of AF1 
(men with CHA2DS2VASc score ≥1; women with CHA2DS-
2VASc score ≥2) will be randomised to one of two groups, 
either an SAMe- TT2R2 score- guided strategy (see table 1) 
Table 1 Components of the SAMe- TT2R2 score
Components Points
S Sex (female) 1
A Age (<60 years) 1
Me Medical history* 1
T Treatment (interacting drug, eg, 
amiodarone)
1
T Tobacco use (within 2 years) 2
R Race (non- Caucasian) 2
Maximum total 8
SAMe- TT2R2 scores 0–2: the patients with AF likely to achieve and 
maintain optimal TTR, and SAMe- TT2R2 scores >2: the patients 
with AF likely poorer responders.
*More than two of the following: hypertension, diabetes mellitus, 
coronary artery disease/myocardial infarction, peripheral atrial 
disease, congestive heart failure, previous stroke, pulmonary 
disease and hepatic or renal disease.
AF, atrial fibrillation; TTR, time in therapeutic range.
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and educational intervention plus usual care versus 
usual care alone. The planned follow- up period is 12 
months. Study sites are seven public hospitals across six 
provinces (Bangkok, Chiang Mai, Chiang Rai, Lampang, 
Khon Kaen and Nakhon Ratchasima) in Thailand. To 
promote generalisability of our findings, these seven 
hospitals are a combination of three university hospitals 
(Maharaj Nakorn Chiang Mai Hospital, Siriraj Hospital, 
and Queen Sirikit Heart Centre of the Northeast) and 
four secondary/tertiary care hospitals (Maharat Nakhon 
Ratchasima Hospital, Chiang Rai Prachanukroh Hospital, 
Nakornping Hospital and Lampang Hospital). The study 
sites and investigators are listed in online supplemental 
appendix 1. The study protocol was approved by the 
Institutional Ethical Committee of each study site and 
by the Institutional Review Board (IRB) of the Ministry 
of Public Health, the Royal Government of Thailand 
(Central Research Committee (CREC) number: COA- 
CREC 007/2020) and registered with the Thai Clinical 
Trials Registry.
Participants
Newly diagnosed adult patients with AF identified and 
referred from cardiology, internal medicine, family medi-
cine and general clinics at the hospitals and referrals from 
primary care will be eligible for enrolment into the study.
Eligibility criteria
Patients must meet all of the following inclusion criteria 
to be eligible for randomisation:
1. ≥18 years of age
2. Newly diagnosed patients with non- valvular AF.
3. ECG- documented AF
4. Warfarin eligible (men with CHA2DS2VASc score ≥1; 
women with CHA2DS2VASc score ≥2)
5. Warfarin naïve (no treatment with anticoagulation 
within the past 12 months; treatment may have started 
within the prior 28 days from randomisation).
6. Able to comply with scheduled visits, treatment plan 
and laboratory tests
7. Able to give informed consent and comply with study 
protocol (with support of a carer)
Patients will be excluded from participation if they 
present with any of the following:
1. Any contraindication to oral anticoagulation
2. Prosthetic cardiac valve or significant valvular heart 
disease with an indication for heart surgery
3. Likelihood of intermittent or permanent discontinua-
tion of warfarin during follow- up (eg, major surgery or 
post- AF ablation)
4. Known active malignancy with a life expectancy less 
than 5 years.
5. Diagnosed significant cognitive impairment prevent-
ing provision of informed consent and/or able to com-
ply with the study protocol.
6. Any disease likely to cause death within 12 months.
The study was originally designed to enrol the patients 
within 5 days of warfarin treatment; however, the average 
referral time was 14 days. The trial steering committee 
agreed to extend the duration between starting warfarin 
and randomisation to 28 days to improve recruitment 
rate, external validity and generalisability of the trials. 
The amended study protocol was approved by the Insti-
tutional Ethical Committee of each study site and by the 
IRB of the Ministry of Public Health, the Royal Govern-
ment of Thailand and updated in the Thai Clinical Trials 
Registry.
Randomisation
After participant eligibility has been confirmed and 
informed consent has been provided, the participant 
will be randomised into the trial. Randomisation will be 
done using a web- based platform with blinded allocation. 
Randomisation will be stratified based on centre, sex (male 
or female) and baseline SAMe- TT2R2 score (0–2, 3–5 and 
6–8). Participants will be randomised at the level of the 
individual in a 1:1 ratio to either the SAMe- TT2R2 score- 
guided strategy and educational intervention plus usual 
care (intervention group) or usual care alone (figures 1 
and 2). Group 1 is the usual care group using warfarin 
(control group). For Group 2, the patients are further 
divided into two groups. Group 2a are patients with an 
SAMe- TT2R2 score of 0–2 who will receive warfarin plus 
usual care. Group 2b are patients with an SAMe- TT2R2 
score  of >2 who will receive warfarin plus the TREAT 
education- behavioural intervention as an adjunct to their 
regular INR monitoring, to improve their TTR.
Trial intervention
As described previously, the TREAT intervention is a 
patient- centred intervention for patients with AF co- devel-
oped through the integration of theoretical and clinical 
frameworks, and patient feedback.26 27 This behaviour- 
change intervention package consists of an educational 
booklet, diary, worksheet and a DVD for reinforcement. 
The educational booklet covers AF causes and conse-
quences, warfarin and its metabolism, stroke risk and 
risk of bleeding on treatment and lifestyle changes (diet, 
alcohol and lifestyle change). The patient DVD contains 
health professionals and ‘expert patient’ narratives that 
covers AF causes, consequences, side effects, treatment 
options, warfarin, INR monitoring, lifestyle changes, 
along with common psychological and physical barriers to 
anticoagulation that patients may experience. The patient 
worksheets include a simple self- calculation of stroke 
risk (CHA2DS2- VASc score), personal barriers to uptake 
of warfarin and discussion of personal goals for lifestyle 
changes. In addition, a self- monitoring diary, including 
diet, alcohol intake (in units), warfarin regimen and INR 
results is also provided.
To overcome the language barrier of the general Thai 
public toward English, the TREAT intervention was 
culturally adapted to fit the local context and then trans-
lated. Forward and backward translation by two bilingual 
experts was performed. A test run of the Thai version of 
the TREAT intervention was conducted among patients 
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with AF with a range of educational ability (Thai literacy 
level is 94%) and age levels. Patient feedback was incorpo-
rated to improve the usability of the Thai- version TREAT 
intervention.
A training session was conducted to prepare all study 
site coordinators (pharmacists and nurses) on how to 
deliver the intervention effectively. To avoid contami-
nation, those who provide the TREAT intervention and 
those who provide usual care will be two different groups 
of pharmacists and nurses. The intervention will be deliv-
ered within 4 weeks of initiating warfarin. Intervention 
fidelity will be ensured by direct observation of random 
sessions at each centre by the trainer. Patients in the usual 
care group will receive training on the OAC management 
from the anticoagulation clinic, and patient information 
about AF and need for warfarin by a healthcare profes-
sional using the standard warfarin education checklist.
Patient and public involvement
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our 
research. The patients involved in the development of 
Thai version of the TREAT intervention.
Outcome measures
The primary outcome is TTR at 12 months. Secondary 
outcomes include (1) TTR at 6 months; (2) thromboem-
bolic and bleeding events from at 12 months; (3) composite 
Figure 1 Study design and recruitment. Group 1: usual care using warfarin (control). Group 2: care pathway designated based 
on stratification of patients using the SAMe- TT2R2 score (warfarin plus usual care). Group 2 care pathways: Group 2a: SAMe- 
TT2R2 score 0–2 (warfarin plus usual care). NB: usual care would include management in the anticoagulation clinic, and patient 
information about AF and need for warfarin by a healthcare professional using the standard warfarin education checklist. Group 
2b: SAMe- TT2R2 score >2 (warfarin plus intensive TREAT education- behavioural intervention as an adjunct to their regular INR 
monitoring to improve their TTR on warfarin). AF, atrial fibrillation; OAC, oral anticoagulants; TTR, time in therapeutic range.
Figure 2 Timing of randomisation, study visits and follow- up.
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MACE outcome of non- fatal MI, non- fatal stroke and cardio-
vascular death and all- cause mortality, in an exploratory anal-
ysis (combined and individually) at 12 months; (4) change in 
patients’ knowledge of AF from baseline to 6 months and 12 
months; (5) cost effectiveness; (6) quality of life at baseline, 
6 months and 12 months assessed using the 5- level EQ- 5D 
version (EQ- 5D- 5L) (Thai version)29 30 and (7) patient 
satisfaction/perceptions of the TREAT intervention. An 
embedded qualitative study will assess patient perceptions of 
the TREAT intervention.
Study procedures and schedules of assessment
Baseline SAMe- TT2R2 score will be calculated (table 1). 
All patients will receive warfarin, dose adjusted to achieve 
a target INR of 2.0–3.0. INR monitoring will be under-
taken at routine intervals (as would occur in usual care) 
and will be recorded over a 12- month period. Patients will 
be randomised as described in figure 1, either to Group 1 
(usual care) or Group 2 (intervention arm), for which the 
trial is powered. Group 2 is a SAMe- TT2R2 scores directed 
management group based on a: patients with AF likeli-
hood of achieving and maintaining optimal TTR (SAMe- 
TT2R2 scores 0–2; Group 2a) and those likely to achieve 
poor TTR (SAMe- TT2R2 scores>2, Group 2b). From our 
prior data, approximately 15%–20% will likely enter 
Group 2a. The primary and secondary outcomes between 
Group 1 and Group 2 (together) will be compared. The 
schedule of assessment is presented in table 2. INR moni-
toring is independent of the intervention (ie, naturalistic) 
as we recognise that the improvement of TTR may be a 
result of more frequent monitoring. Patients in all groups 
will have their INR monitored as they would if they were 
not in the trial (by anticoagulation services which are 
separate from the trial and who are blinded to treatment 
allocation).
Data collection and management
Medical records of the participating hospitals serve as the 
source data, including clinical information and labora-
tory values, which are accessible and maintained in accor-
dance to national standards and regulations. Outcome 
data will be extracted from participant’s clinical notes and 
laboratory reports into an electronic case record form 
(CRF). For long- term storage, clinical data will be elec-
tronically archived at Faculty of Medicine, Chiang Mai 
University, Thailand, as per the regulatory requirements 
for good clinical practice and in line with the Medical 
Research Council requirements and local policies.
The questionnaires will be completed by the patient. 
For those with literacy problems, the questionnaires will 
be read out to the participant, the participant will respond 
to each question and their responses will be recorded by 
the staff member administering the questionnaires.
Trial data will be captured in a Research Electronic Data 
Capture (REDCap), secure SQL server database. An inde-
pendent data monitoring committee (DMC), including 
both local and international experts, has been appointed 
and convened. Interim analyses of major outcome measures 
and safety data will be conducted and provided in strict 
Table 2 Study visits schedule
Clinical assessment
a. Demographic information: age, sex, ethnicity, education level, height (cm), weight (kg), body mass index, smoking status and alcohol use
b. Medical history: history of arterial hypertension, heart failure, diabetes mellitus, coronary artery disease (myocardial infarction, PCI and CABG), 
peripheral artery disease, stroke, transient ischaemic attack, systemic embolism, COPD, chronic kidney disease, chronic liver disease, thyroid 
disease and bleeding event
c. Physical examination, blood pressure, heart rate, EHRA and NYHA class
d. Concomitant medical therapy
OAC therapy education: all patients—a standard OAC education session conducted by a healthcare professional about the clinical significance and 
management of OAC therapy
Questionnaires: atrial fibrillation knowledge questionnaires, patient satisfaction (Likert scale) and EQ- 5D- 5L (Thai version)
Health economics assessment: EQ- 5D- 5L (Thai version), AF, warfarin and clinical event- related healthcare resource use and intervention costs
Follow- up of clinical events: TTR, composite of thromboembolism, major bleeding and all- cause death (in all patients)
  Baseline M1±7D M2±7D M6±14D M12±14D
Clinical assessment a,b,c,d c c c c,d
ECG x         
INR** x x x x x
Standard OAC therapy education x         
TREAT intervention   x       
Questionnaires x     x x
Qualitative assessment x†     x   
Health economic assessment x     x x
Follow- up of clinical events       x x
*INR monitoring is mandatory during the 12- month follow- up period for all patients, with frequency as per usual care conducted by anticoagulation clinics.
†Baseline interviews of patients will take place within 4 weeks of receiving the intervention.
AF, atrial fibrillation; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; EQ- 5D- 5L, The 5- level EQ- 5D 
version; INR, international normalised ratio; OAC, oral anticoagulants; PCI, percutaneous coronary intervention.
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confidence to the DMC. Any decision to stop the trial early 
will be based on the balance of efficacy and safety.
Sample size and power calculations
Most recent studies suggest that the mean TTR in Thai 
patients receiving warfarin is in the range of 50%–55%.11 12 
Since an improvement of 10% in the mean TTR is likely 
to be clinically meaningful, we assume a 10% difference 
in 12- month TTR with 90% power and 5% significance 
level for our sample size calculation and using an SD of 
‘26’ as observed in a previous Thai study to determine the 
sample size estimates. Hence, to detect a 10% mean differ-
ence in TTR at 12 months, using two- sided test, sample 
size for randomisation in a 1:1 ratio would be 288 or 144 
per arm. Assuming and adjusting for a 10% attrition/loss 
to follow- up rate, a total sample size of 320 patients or 160 
per arm is needed.
Statistical analysis
Continuous variables will be presented as mean (SD), or 
median (IQR), as appropriate; categorical variables will be 
reported as counts with percentages. Descriptive statistics 
will be presented for baseline demographic and clinical 
information. For all major outcomes, summary statistics 
and differences between groups (eg, mean differences 
and relative risks) will be presented, with CIs and p values 
from two- sided tests also given.
All analyses will be based on the intention- to- treat 
(ITT) principle. The primary comparison groups will be 
composed of those randomised to Group 1, usual care, 
versus those randomised to Group 2, the SAMe- TT2R2 
score- guided strategy with the TREAT intervention (plus 
usual care). All outcomes will be adjusted for the strati-
fication variables (centre, sex and baseline SAMe- TT2R2 
score) where possible. Two- tailed p values <0.05 will be 
considered statistically significant. No adjustment for 
multiple comparisons will be made.
Subgroup analysis
Subgroup analyses will be conducted for the stratification 
variable sex only. All other stratification variables will be 
used only to ensure that the two groups are balanced in 
terms of these important variables. Subgroup analyses 
will be limited to the primary outcome only. Tests for 
statistical heterogeneity (eg, by including the treatment 
group by subgroup interaction parameter in the regres-
sion model) will be performed prior to any examina-
tion of effect estimates within subgroups. The results of 
subgroup analyses will be treated with caution and will be 
used for the purposes of hypothesis generation only.
Missing data and sensitivity analyses
Missing and ambiguous data will be queried using a data 
clarification system, and will focus on data required for 
trial outcome analysis and safety reporting. Every attempt 
will be made to collect full follow- up data on all study 
participants. A sensitivity analysis will be performed on the 
primary outcome measure only to examine the possible 
impact of any missing data for the primary outcome. This 
will include the use of multiple imputation using chained 
equations. Further sensitivity analysis will also be done 
if a substantial number of participants do not comply 
with randomised allocated group and so a per- protocol 
analysis may also be conducted. Any sensitivity analyses 
will not, irrespective of their differences, supplant the 
planned primary analyses.
Interim analysis
Interim analyses of safety and efficacy for presentation to 
the independent DMC will take place during the study. 
The committee will meet prior to study commencement 
to agree the manner and timing of such analyses. The 
analysis of the primary and major secondary outcomes 
and full assessment of safety (adverse events and serious 
adverse events) will be performed at annual intervals. 
Criteria for stopping or modifying the study based on this 
information will be ratified by the DMC.
Planned final analyses
The final analysis for the study will occur once the last 
randomised participant has completed the 12- month 
follow- up and any corresponding outcome data have 
been entered onto the study database and validated as 
being ready for analysis.
Withdrawal
Patients may withdraw consent from the study at any 
time. Patients may also withdraw from trial treatment but 
continue with study follow- up and data collection as per 
the protocol. If the withdrawal is initiated by a healthcare 
professional, full details for the reason for withdrawal will 
be recorded on the case report forms. In all other cases, 
a simple statement reflecting the patient’s preference 
will be noted. The patients who are switched to NOACs 
will be followed for clinical events. The INR data will be 
collected to the end of warfarin treatment for the TTR 
calculation and analysis as ITT analysis.
Analysis of outcome measures
Primary outcome
The primary outcome is the TTR at 12 months and differ-
ences in TTR between the intervention and usual care 
groups will be examined using a linear regression model. 
Results will be presented as mean difference and 95% CI. 
A key assumption for this analysis is that the data will be 
normally distributed; this assumption will be examined 
visually based on the residuals from the fitted model. If 
data are deemed not to be normally distributed, then the 
Mann- Whitney U test will be used for analysis.
Secondary outcomes
The secondary endpoints for the trial includes contin-
uous, categorical and time- to- event data items. Any 
secondary endpoints that are continuous in nature will 
be analysed in the same way as described for the primary 
outcome. For dichotomous secondary endpoints, the 
proportion of participants and percentages will be 
compared between arms using a log- binomial model. 
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Relative risks and 95% CIs will be calculated. For any 
time- to- event outcomes these will be compared between 
treatment arms by using survival analysis methods. Cox 
proportional hazards model will be used and treatment 
effects will be expressed as HRs with 95% CIs. Kaplan- 
Meier survival curves will be constructed for visual presen-
tation of time- to- event comparisons.
Qualitative study
Qualitative data will be obtained directly from patient 
interviews and interviews with healthcare professionals 
delivering the intervention as part of an embedded quali-
tative substudy. A purposive sample of 10–15 participants 
from the intervention arm will take part in one- to- one 
semi- structured interviews with a qualitative researcher, at 
two time- points (within 4 weeks of the intervention and 
at 6- months follow- up). Interviews will explore partici-
pants’ experience of AF; of receiving the TREAT inter-
vention; their perspectives on the utility of different 
interventions components; as well as behavioural modi-
fications resulting from the intervention. Staff delivering 
the intervention at each study site will also be interviewed 
to understand their perceptions of the TREAT interven-
tion and their experience of delivering it to patients. A 
thematic analysis of interview content will be informed by 
the framework analytic approach. Audio- recorded inter-
views will be translated and transcribed into English in 
order to facilitate team- based analysis by Thai and English 
research team members.31
Health economics analysis
The economic evaluation will determine the cost effective-
ness of the intensive educational intervention versus usual 
care. The evaluation will take the form of an incremental 
cost–utility analysis to estimate cost per quality adjusted 
life year (QALY) over 12- months follow- up from a Thai-
land health service perspective. If differences in TTR are 
achieved in the trial, a longer- term Markov model- based 
cost per QALY analysis will be also undertaken.
Data collection
Data will be collected on healthcare utilisation required 
for the intervention, warfarin therapy and monitoring, 
and healthcare visits, hospitalisations, investigations and 
medication related to thromboembolism, bleeding and 
management of AF. Information will be collected at the 
6- month and 12- month patient visits from trial CRFs and 
hospital records. Additional costings, such as those associ-
ated with transportation to the hospital, will be collected 
from the patients. The EQ- 5D- 5L (Thai version) ques-
tionnaire will be administered to participants at baseline, 
6 months and 12 months to estimate QALYs.
Data analysis
Unit costs from standard Thai sources will be applied to all 
healthcare resource use items, and mean resource use (for 
each category of healthcare usage) and mean total costs will 
be calculated for both trial arms. The current Thailand’s 
value set will be applied to patient EQ- 5D- 5L responses to 
obtain utility scores and QALYs will be calculated using the 
area under the curve approach. Multiple imputation will be 
used to impute all missing values for the EQ- 5D- 5L and total 
cost estimates for non- responders. As cost and QALY data 
are likely to have a skewed distribution, a non- parametric 
comparison of means (using bootstrapping) will be under-
taken. A cost–consequence analysis will initially be reported, 
describing all the important results relating to resource use, 
costs and consequences. Incremental cost- effectiveness and 
cost–utility analyses will then be undertaken to estimate the 
incremental cost per QALY gained at 12 months, with adjust-
ment for baseline covariates. The robustness of the results 
will be explored using sensitivity analysis. Cost- effectiveness 
acceptability curves (CEACs) will also be produced to reflect 
the probability that the intervention will be cost effective at 
different cost per QALY willingness to pay thresholds.
Model-based analysis
If the trial data show a benefit in TTR due to the inter-
vention, trial results will be extrapolated using a Markov 
model- based cost per QALY. This model will take into 
account the long- term impact of anticoagulant control 
on thromboembolism and bleeding over the patient’s 
lifetime, with costs and outcomes discounted at 3%. The 
model structure will be informed by previously published 
modelling studies and expert opinion. Extensive deter-
ministic sensitivity analysis using predefined ranges will 
be undertaken to explore which model parameters have 
most impact on cost effectiveness. Parameter estimates 
will be incorporated into the model as distributions to 
allow for a probabilistic sensitivity analysis, with CEACs 
constructed to assess the probability of cost effectiveness 
at different cost per QALY willingness to pay thresholds.
Trial status
The study protocol V.2.1 dated 19 August 2019 was 
approved by the Institutional Ethical Committee of each 
study site and by the IRB of the Ministry of Public Health, 
the Royal Government of Thailand (CREC number: COA- 
CREC 007/2020) and the study protocol had amended 
and approved at V.3.0 dated 9 June 2020. The recruitment 
of participants started in 31 January 2020. Last patient 
recruitment is expected in May 2021. Data collection is 
expected to be completed in December 2021.
Dissemination
Results of this trial will be submitted for publication in a 
peer- reviewed journal. The manuscript will be prepared 
by the principal investigators or their delegates and 
authorship will be determined by the trial publication 
policy. Participants will be informed of the outcome of 
the trial via a link to a preview of the publication. A lay 
summary will also be provided via email or posted to 
participants prior to publication.
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